Apixaban hits the buffers in Phase III
This article was originally published in Scrip
Pfizerand Bristol-Myers Squibb's investigational Factor Xa inhibitor apixaban has missed the primary endpoint in the Phase III ADVANCE-1 study for the prevention of venous thromboembolism in patients undergoing total knee replacement surgery, an early analysis of the data indicates.
You may also be interested in...
The Russian ministry of health has raised eyebrows by approving a vaccine against SARS-CoV-2 just weeks after its first clinical trials in 76 volunteers. Phase III confirmatory studies await for the adenovirus-based product but a mass vaccination plan is slated to begin in October.
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.